Peter W Stacpoole MD
Diabetes, Lipid Metabolism
Professor, Medicine, University of Florida College of Medicine
Join to view full profile
1600 SW Archer RdGainesville, FL 32610
Dr. Stacpoole is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Vanderbilt University Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1978 - 1980- Vanderbilt University Medical CenterResidency, Internal Medicine, 1976 - 1978
Vanderbilt University School of MedicineClass of 1976
UC San FranciscoPhD, Pharmacology, 1968 - 1972
Certifications & Licensure
CA State Medical License 1980 - Present
FL State Medical License 1981 - 2027
TN State Medical License 1978 - 1984
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
- Elected Member Royal Society of Physicians, 2000
- Elected Member The American Society for Clinical Investigation, 1985
Clinical Trials
Publications & Presentations
PubMed
- A novel approach to reverse Warburg metabolism in patients with recurrent glioblastoma: A phase II pharmacodynamic study of dichloroacetate.Carolyn O Dirain, Stuart A Grossman, Xiaobu Ye, Priya Sambasivan, Puranjay Shori
Neuro-Oncology Advances. 2026-08-25 - 3 citationsExtension of lifespan by epicatechin, halofuginone and mitoglitazone in male but not female genetically heterogeneous mice.Randy Strong, James F Nelson, Molly A Bogue, Jerry R Colca, Martin Denzel
Geroscience. 2026-06-01 - 1 citationsShould the "mitochondrial cocktail" be a default option? An opinion.Peter W Stacpoole, Stephen D Cederbaum
Molecular Genetics and Metabolism. 2025-12-01
Grant Support
- Combined pharmacologic and AAV gene therapy of pyruvate dehydrogenase deficiencyUNIVERSITY OF FLORIDA2026–2028
- Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 09172019UNIVERSITY OF FLORIDA2021–2025
- Personalized dosing of dichloroacetate for the treatment of rare and common diseasesMEDOSOME BIOTEC, LLC2017–2024
- Phase 3 Trial Of Coenzyme In Mitochondrial DiseaseFood And Drug Administration2006–2011
- Planning Grant For Phase 3 Trial Of Dichloroacetate In PDH DeficiencyEunice Kennedy Shriver National Institute Of Child Health &Human Development2010
Industry Relationships
- Chief Scientific Officer, Praesidio Pharma, LLCFocus on research involving dichloroacetate (DCA) and related compounds2018 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
